OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing a new Mode of Action. OMEICOS’ novel therapeutic strategy is based upon the discovery of natural metabolites of omega-3 fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other anti-arrhythmic drugs, OMEICOS’ substances activate an endogenous cardio-protective signaling pathway that not only stabilizes the heart rhythm but shall provide curative effects to the diseased organ by preventing its electrical and structural remodeling.
💡 You’re a corporate or investor and looking for startups that are innovating in the same market as OMEICOS Therapeutics? We’re happy to assist you with our Startup Sourcing service.